FDA Fights Back Against ViroPharma's Generic Vancocin Suit

Law360, New York (September 5, 2012, 3:01 PM EDT) -- ViroPharma Inc. doesn't deserve three more years of exclusive rights for its Vancocin, the U.S. Food and Drug Administration told a Washington federal judge Tuesday in a motion to dismiss a lawsuit over the agency's approval of generic versions of the antibiotic.

In its bid to have tossed the suit challenging approval of three generic forms of the gastrointestinal treatment, the FDA said the company hasn’t devised new uses for the medicine warranting continued monopoly protection. The agency downplayed the significance of Vancocin labeling changes it...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

VIROPHARMA INCORPORATED v. HAMBURG et al


Case Number

1:12-cv-00584

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Ellen S. Huvelle

Date Filed

April 13, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.